BIOMARIN PHARMACEUTICAL INC — Form 10-Q
Filed November 3, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 72/100
What the filing says
BioMarin and Ascendis settled all pending patent litigation effective August 28, 2026, dismissing cases listed in Schedule 1 by September 24, 2026. BioMarin granted Ascendis a non-exclusive, worldwide, royalty-bearing license under BioMarin's C-type natriuretic peptide patents covering Ascendis's YUVIWEL (navepegritide) product, retroactively to Ascendis's first U.S. commercial sale on April 6, 2026. Ascendis pays BioMarin 20% royalties on U.S. Net Sales and 18% on EU/Brazil/South Korea Net Sales during a Royalty Term ending May 20, 2030; thereafter, the license converts to fully paid-up and royalty-free. Both parties executed mutual releases, covenants not to sue, and waivers of regulatory exclusivity rights.
Why this rating
Settlement eliminates material IP litigation risk for BioMarin and creates recurring revenue stream (18–20% of Ascendis YUVIWEL sales through May 2030). Without disclosed net sales figures, revenue impact cannot be quantified precisely, but deal is strategically significant—resolves competitive threat from Ascendis's approved CNP product while preserving BioMarin's own VOXZOGO rights. Relative to $6.7B market cap, outcome is material but not transformational; suitable for significant category given IP resolution and ongoing royalty cash flow.
Price action (we called it neutral)
before filing · preread $55.66 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.